S. Grancha

发表

Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors

M. Bravo, B. Da Rocha-Souto, S. Grancha, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Kinetics of the interaction between anti‐FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance

J. Aznar, A. Moret, S. Grancha, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010

J. Oldenburg, A. Federici, N. Ewing, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

DETAILED LOCALIZATION OF TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR MRNA EXPRESSION AND ANTIGEN IN ATHEROSCLEROTIC PLAQUE ON HUMAN CORONARY ARTERY

M. Chirivella, F. España, A. Estellés, 1998 .

Activated protein C resistance phenotype in patients with antiphospholipid antibodies.

F. España, A. Estellés, C. Falcó, 1997, The Journal of laboratory and clinical medicine.

PAI‐1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects

F. España, A. Estellés, C. Falcó, 2000, British journal of haematology.

The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status.

M. Tortajada, J. Gilabert, F. España, 1995, American journal of obstetrics and gynecology.

Lipoprotein(a) Levels and Isoforms and Fibrinolytic Activity in Postmenopause – Influence of Hormone Replacement Therapy

J. Gilabert, F. España, A. Estellés, 1999, Thrombosis and Haemostasis.

Plasminogen Activator Inhibitor-1 (PAI-1) Promoter 4G/5G Genotype and Increased PAI-1 Circulating Levels in Postmenopausal Women with Coronary Artery Disease

J. Gilabert, F. España, A. Estellés, 1999, Thrombosis and Haemostasis.

Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.

J. Gilabert, F. España, A. Estellés, 1999, Thrombosis and haemostasis.

Management of bleeding disorders: basic science

E. Santagostino, S. Grancha, F. Ofosu, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation.

Y. Eguchi, J. Gilabert, A. Estellés, 1994, Blood.

Abnormal Expression of Type 1 Plasminogen Activator Inhibitor and Tissue Factor in Severe Preeclampsia

J. Gilabert, F. España, A. Estellés, 1998, Thrombosis and Haemostasis.

Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion.

F. España, A. Estellés, J. Aznar, 1999, Haematologica.

Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease.

J. Gilabert, M. Chirivella, F. España, 1996, The American journal of pathology.

The burden of inhibitors in haemophilia patients

V. Jiménez‐Yuste, S. Grancha, G. Auerswald, 2016, Thrombosis and Haemostasis.

Neutralizing capacity of inhibitors on FVIII is lower for natural FVIII/VWF complex than for isolated FVIII: in vitro comparative study in eleven different therapeutic FVIII concentrates

M. Bravo, S. Grancha, J. Jorquera, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study

V. Jiménez‐Yuste, M. Álvarez‐Román, M. Bravo, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Human mesenchymal stem cells maintain their phenotype, multipotentiality, and genetic stability when cultured using a defined xeno-free human plasma fraction

S. Grancha, R. Gajardo, J. Díez, 2017, Stem Cell Research & Therapy.

Increased Albumin Oxidation in Cerebrospinal Fluid and Plasma from Alzheimer’s Disease Patients

A. Ruiz, M. Boada, S. Grancha, 2018, Journal of Alzheimer's disease : JAD.

PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects

Justo Aznar, F. España, A. Estellés, 2000 .

Decreased Expression of PAI-2 mRNA and Protein in Pregnancies Complicated with Intrauterine Fetal Growth Retardation

J. Gilabert, M. Chirivella, F. España, 1996, Thrombosis and Haemostasis.

Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation.

J. Gilabert, M. Chirivella, F. España, 1994, Gynecologic and obstetric investigation.

Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia.

J. Gilabert, F. España, A. Estellés, 1995, Human reproduction.

Characterization of antibodies in human immunoglobulin products from different regions worldwide

Berta Pons, S. Grancha, P. Maduell, 2021, International Journal of Infectious Diseases.

Human mesenchymal stem cells maintain their phenotype, multipotentiality, and genetic stability when cultured using a defined xeno-free human plasma fraction

S. Grancha, R. Gajardo, J. Díez, 2017, Stem Cell Research & Therapy.

Abnormal Expression ofPlasminogen Activator Inhibitors inPatients withGestational Trophoblastic Disease

M. Chirivella, S. Grancha, T. Thinnes, 1996 .